APONVIE Drug Patent Profile
✉ Email this page to a colleague
When do Aponvie patents expire, and when can generic versions of Aponvie launch?
Aponvie is a drug marketed by Heron Theraps Inc and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has nine patent family members in five countries.
The generic ingredient in APONVIE is aprepitant. There are twenty-six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aponvie
A generic version of APONVIE was approved as aprepitant by SANDOZ on September 24th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for APONVIE?
- What are the global sales for APONVIE?
- What is Average Wholesale Price for APONVIE?
Summary for APONVIE
| International Patents: | 9 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Patent Applications: | 2,252 |
| Drug Prices: | Drug price information for APONVIE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for APONVIE |
| What excipients (inactive ingredients) are in APONVIE? | APONVIE excipients list |
| DailyMed Link: | APONVIE at DailyMed |
Paragraph IV (Patent) Challenges for APONVIE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| APONVIE | Intravenous Emulsion | aprepitant | 32 mg/4.4 mL | 216457 | 1 | 2023-11-07 |
US Patents and Regulatory Information for APONVIE
APONVIE is protected by eleven US patents.
Patents protecting APONVIE
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR PREVENTING OF POST-OPERATIVE NAUSEA AND VOMITING
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR PREVENTING POST-OPERATIVE NAUSEA AND VOMITING
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Emulsion formulations of aprepitant
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heron Theraps Inc | APONVIE | aprepitant | EMULSION;INTRAVENOUS | 216457-001 | Sep 16, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Heron Theraps Inc | APONVIE | aprepitant | EMULSION;INTRAVENOUS | 216457-001 | Sep 16, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Heron Theraps Inc | APONVIE | aprepitant | EMULSION;INTRAVENOUS | 216457-001 | Sep 16, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Heron Theraps Inc | APONVIE | aprepitant | EMULSION;INTRAVENOUS | 216457-001 | Sep 16, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Heron Theraps Inc | APONVIE | aprepitant | EMULSION;INTRAVENOUS | 216457-001 | Sep 16, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for APONVIE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme B.V. | Emend | aprepitant | EMEA/H/C/000527 Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. |
Authorised | no | no | no | 2003-11-11 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for APONVIE
See the table below for patents covering APONVIE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 106852118 | 阿瑞吡坦乳剂制剂 (Emulson formulations of aprepitant) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2016044784 | ⤷ Sign Up | |
| Japan | 2022092040 | アプレピタントのエマルジョン製剤 | ⤷ Sign Up |
| Japan | 6741655 | ⤷ Sign Up | |
| Japan | 2017533183 | アプレピタントのエマルジョン製剤 | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for APONVIE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0734381 | PA2004002 | Lithuania | ⤷ Sign Up | PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111 |
| 0734381 | 04C0010 | France | ⤷ Sign Up | PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111 |
| 0748320 | 08C0019 | France | ⤷ Sign Up | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
| 0734381 | PA2004002,C0734381 | Lithuania | ⤷ Sign Up | PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111 |
| 0734381 | 3/2004 | Austria | ⤷ Sign Up | PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
